KR20220016105A - 통풍 또는 고요산혈증을 치료하기 위한 화합물 - Google Patents

통풍 또는 고요산혈증을 치료하기 위한 화합물 Download PDF

Info

Publication number
KR20220016105A
KR20220016105A KR1020217041035A KR20217041035A KR20220016105A KR 20220016105 A KR20220016105 A KR 20220016105A KR 1020217041035 A KR1020217041035 A KR 1020217041035A KR 20217041035 A KR20217041035 A KR 20217041035A KR 20220016105 A KR20220016105 A KR 20220016105A
Authority
KR
South Korea
Prior art keywords
compound
effective amount
therapeutically effective
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217041035A
Other languages
English (en)
Korean (ko)
Inventor
순퀴 얀
리타인 예
롱지 얀
잔콩 센
Original Assignee
아쓰로시 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아쓰로시 테라퓨틱스, 인크. filed Critical 아쓰로시 테라퓨틱스, 인크.
Publication of KR20220016105A publication Critical patent/KR20220016105A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
KR1020217041035A 2019-05-14 2020-05-13 통풍 또는 고요산혈증을 치료하기 위한 화합물 Pending KR20220016105A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962847519P 2019-05-14 2019-05-14
US62/847,519 2019-05-14
PCT/US2020/032725 WO2020232156A1 (en) 2019-05-14 2020-05-13 Compound for treating gout or hyperuricemia

Publications (1)

Publication Number Publication Date
KR20220016105A true KR20220016105A (ko) 2022-02-08

Family

ID=73288915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217041035A Pending KR20220016105A (ko) 2019-05-14 2020-05-13 통풍 또는 고요산혈증을 치료하기 위한 화합물

Country Status (14)

Country Link
US (1) US20220242841A1 (https=)
EP (1) EP3968989A4 (https=)
JP (1) JP7656548B2 (https=)
KR (1) KR20220016105A (https=)
CN (1) CN113874014A (https=)
AU (2) AU2020274165A1 (https=)
BR (1) BR112021022843A2 (https=)
CA (1) CA3140412A1 (https=)
IL (1) IL288034B1 (https=)
MA (1) MA55973A (https=)
MX (1) MX2021013980A (https=)
SG (1) SG11202112562XA (https=)
TW (1) TW202108561A (https=)
WO (1) WO2020232156A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250120897A (ko) 2024-01-31 2025-08-11 충남대학교산학협력단 사이클로덱스트린과 컨쥬게이션된 중합체 나노약물을 포함하는 통풍 치료용 약학 조성물 및 치료방법

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202105743RA (en) 2018-12-06 2021-06-29 Arthrosi Therapeutics Inc Methods for treating or preventing gout or hyperuricemia
KR102946486B1 (ko) 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
KR20230024354A (ko) * 2020-06-10 2023-02-20 아쓰로시 테라퓨틱스, 인크. 만성 신장 질환을 치료 또는 예방하는 방법
WO2023058975A1 (ko) * 2021-10-07 2023-04-13 (주)이노보테라퓨틱스 벤조퓨라닐 히드록시페닐 메타논 유도체를 포함하는 hsp47 억제용 약학 조성물
TW202330485A (zh) * 2021-12-02 2023-08-01 美商安索治療公司 用於治療或預防痛風或高尿酸血症之化合物的結晶形式
WO2023125667A1 (en) * 2021-12-30 2023-07-06 Arthrosi Therapeutics, Inc. Preparation of a compound for the treatment of gout or hyperuricemia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962362B2 (en) * 2012-03-29 2018-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting EYA tyrosine phosphatase
EP3484862B1 (en) * 2016-07-18 2021-09-01 Arthrosi Therapeutics, Inc. Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia
US20210130312A1 (en) * 2018-04-03 2021-05-06 Children's Hospital Medical Center Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension
KR102946486B1 (ko) * 2018-12-06 2026-03-31 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250120897A (ko) 2024-01-31 2025-08-11 충남대학교산학협력단 사이클로덱스트린과 컨쥬게이션된 중합체 나노약물을 포함하는 통풍 치료용 약학 조성물 및 치료방법

Also Published As

Publication number Publication date
JP2022533958A (ja) 2022-07-27
MA55973A (fr) 2022-03-23
JP7656548B2 (ja) 2025-04-03
CN113874014A (zh) 2021-12-31
BR112021022843A2 (pt) 2022-03-03
WO2020232156A1 (en) 2020-11-19
EP3968989A4 (en) 2022-12-28
IL288034B1 (en) 2026-04-01
SG11202112562XA (en) 2021-12-30
IL288034A (en) 2022-01-01
EP3968989A1 (en) 2022-03-23
MX2021013980A (es) 2022-04-01
TW202108561A (zh) 2021-03-01
AU2026202224A1 (en) 2026-04-09
AU2020274165A1 (en) 2022-01-06
CA3140412A1 (en) 2020-11-19
US20220242841A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
JP7656548B2 (ja) 痛風または高尿酸血症を処置するための化合物
KR102946486B1 (ko) 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
JP7528080B2 (ja) 痛風または高尿酸血症を処置または予防するための方法
US20250066316A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
KR102956127B1 (ko) 통풍 또는 고뇨산혈증의 치료 또는 예방 방법
EA049585B1 (ru) Соединение для лечения подагры или гиперурикемии
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40060723A (en) Compound for treating gout or hyperuricemia
HK40056575A (en) Methods for treating or preventing gout or hyperuricemia
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574B (zh) 用於治疗或预防痛风或高尿酸血症的化合物的晶型

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000